Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch
Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology.
Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care
While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.
presented by
Hospital and Payer AI Governance Is at a Crossroads
Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats?
Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.
When AI Gets Medicine Wrong, Who’s Liable?
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?